Analysis of Financial Performances for REGENERON: Comparison with AMGEN, GILEAD, and BIOGEN

As a matter of fact, plenty of biomedicne companies are grown faster especially after the impact of Covid. This paper analyzes the financial performance of REGENERON in comparison to its peers AMGEN, GILEAD, and BIOGEN. The study reveals that REGENERON exhibits robust financial health, characterized by a high and steadily rising gross margin throughout 2023, a revenue growth rate of 7.76%, and strong profitability driven by its popular Eylea series in the ophthalmology market. Conversely, GILEAD faces significant challenges, including declining gross margins, stagnant revenue, and unfavorable investment metrics such as a negative PEG ratio and increased P/E ratio. AMGEN shows stable performance with moderate growth, while BIOGEN struggles with lower profitability and fluctuating financial metrics. According to the results, REGENERON is well-positioned for continued growth, provided it maintains operational efficiency and adapts to competitive market dynamics. This research offers critical insights into the financial strategies and market positions of leading biopharmaceutical companies, serving as a valuable guide for investors and stakeholders in making informed decisions in a rapidly evolving industry.